Herpes Simplex Virus (Hsv) Vaccines MarketSize and Trends

Global Herpes Simplex Virus (HSV) Vaccines Market Drivers

Factors such as extensive research and development is expected to support global herpes simplex virus (HSV) vaccines market growth over the forecast period. Leading players in the market such as GlaxoSmithKline (GSK), Sanofi SA, and others have HSV vaccines in the development phases. GSK’s vaccine SB208141 completed phase III studies in 2009, which started in 2003. GSK carried out several other clinical trial studies on the same vaccine, considering various different parameters and formulations (with or without monophosphoryl lipid adjuvant [MPL]). Sanofi Pasteur has vaccine HSV529 for HSV-2 is in phase I, whose clinical trial study started in 2015 and completed in 2018. Moreover, Vical, Inc. has VCL-HB01, whose phase I study started in September 2016, and completed in December 2018. Furthermore, Genocea Biosciences, Inc. vaccine GEN-003 is in phase II study where the study started in November 2015 and completed in May 2017. The company also carried out various trial studies with the same vaccine by using an adjuvant Matrix-M2 (It is human respiratory syncytial virus, derived from Quillaja saponins, cholesterol, and phosphatidylcholine). Therefore, robust pipeline is expected to propel global herpes simplex virus (HSV) vaccines market growth over the forecast period.

According to Centers for Disease Control and Prevention (CDC) in 2015 HSV-1 prevalence was 47.8% while HSV-2 was 11.9% in the U.S. According to the same source, linear increase in prevalence for both HSV-1 and HSV-2 in people aged within 14-19 is 27%, for population aged within 20–29 is 41%, and for the age ranging within 30–39 and 40–49 it is 54.1% and 59.7%, respectively. According to the World Health Organization (WHO), in 2017, around 3.7 billion people (67%) under age 50 years suffered from HSV-1 infection, and 417 million (11%) people aged 15-49 years suffered from HSV-2 infection, globally. This high rate of prevalence has created need for prevention and treatment of HSV, which is expected to support global herpes simplex virus (HSV) vaccines market growth.